“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Filippo Montemurro, Laura Iezzi et al.|Oncotarget|2016Cited by 43
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA studyChiara Molinelli, Lucia Del Mastro, Marco Bruzzone et al.|European Journal of Cancer|2024Cited by 15
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Nicola Tinari, Eriseld Krasniqi et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational studyFrancesca Sofia Di Lisa, Enzo Veltri, Eriseld Krasniqi et al.|Frontiers in Oncology|2023Cited by 9
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello, Fabio Puglisi, Eva Blondeaux et al.|npj Breast Cancer|2024Cited by 2